Cys-peptide mediates the protective role in preeclampsia-like rat and cell models

Area of Science:

• Reproductive Biology
• Biochemistry
• Pharmacology

Background:

• Preeclampsia (PE) is a serious pregnancy complication characterized by hypertension and proteinuria.
• Endothelial dysfunction and impaired trophoblast cell function contribute to PE pathogenesis.
• Current treatments for PE are limited, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential protective effects of a novel cysteine-based peptide (Cys-peptide) in preeclampsia animal and cell models.
• To evaluate Cys-peptide's impact on key pathological features of preeclampsia, including hypertension, proteinuria, fetal growth restriction, and endothelial dysfunction.

Main Methods:

• Cys-peptide's effects were assessed in lipopolysaccharide (LPS)-induced preeclampsia-like rat models, evaluating hypertension, proteinuria, and fetal growth restriction (FGR).
• In vitro studies utilized human umbilical vascular endothelial cells (HUVECs) and HTR-8 cells to assess Cys-peptide's protection against TNFα-induced cytotoxicity, endothelial dysfunction, and impaired trophoblast cell migration and invasion.
• Key molecular markers, including soluble fms-like tyrosine kinase-1 (sFlt-1), endothelin-1 (ET-1), and tissue plasminogen activator (tPA) mRNA expression, were analyzed.

Main Results:

• Cys-peptide significantly ameliorated hypertension, proteinuria, and FGR in preeclampsia-like rat models.
• In vitro, Cys-peptide attenuated TNFα-induced cytotoxicity by reducing sFlt-1, ET-1, and tPA mRNA expression.
• Cys-peptide restored endothelial function, rescued angiogenesis, and reversed impaired trophoblast cell migration and invasion.

Conclusions:

• Cys-peptide demonstrates significant beneficial effects in both preeclampsia-like rat and cell models.
• These findings suggest that Cys-peptide holds promise as a novel therapeutic candidate for preeclampsia (PE).